All News

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

A new study indicates that there are age-associated gender differences seen in the disease burden of chronic obstructive pulmonary disorder (COPD), with younger women more severely affected.

New recommendations urge health care providers to offer pre-exposure prophylaxis (PrEP) to individuals at high risk of HIV.

Purdue University researchers have developed a shoe insole that could help make the healing process more portable for the 15% of Americans who develop ulcers as a result of diabetes.

The FDA has granted an accelerated approval to larotrectinib (Vitrakvi, Loxo Oncology) for the treatment of adult and pediatric patients with solid tumors that have an NTRKgene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

The FDA has granted an accelerated approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion.

Top news of the day from across the health care landscape.

Officials with the FDA have approved Genentech’s single-dose, prefilled autoinjector ACTPen 162 mg/0.9 mL for tocilizumab (Actemra) for patients with rheumatoid arthritis (RA), giant cell arteritis (GCA), and 2 forms of juvenile arthritis.

The single-dose, prefilled autoinjector for tocilizumab (Actemra) offers an additional option for patients with rheumatoid arthritis, giant cell arteritis, and 2 forms of juvenile arthritis.

Top news of the day from across the health care landscape.

Myriad reasons may prevent patients from accessing specialty drugs, which create significant problems for patients in need of treatment.

Antiretroviral drug treatment was not found to be a cause of the higher prevalence of hypertension in persons infected with HIV.

FDA officials cited the possibility of a cardiovascular (CV) safety risk based on Zafgen's prior compound and outlined potential paths for moving forward.

More than 160 patients have thus far been treated with investigational therapeutics under an ethical framework developed by WHO.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

The single-dose, prefilled autoinjector for tocilizumab (Actemra) offers an additional option for patients with rheumatoid arthritis, giant cell arteritis, and 2 forms of juvenile arthritis.

Opioid use in the United States has exploded in recent years, from about 100 million prescriptions filled in 1992 to nearly 250 million in 2015.

In this series, Jill Drury, PharmD, a clinical pharmacy specialist, provides patients with "Brown Bag" consultations. Patients bring to the pharmacy their current medications and over-the-counter products, giving the pharmacist an additional resource for pharmaceutical counsel. In this video, a patient with Parkinson's disease is experiencing depression. He is a military veteran who is unsure of the medical instructions given by the VA.

Our editors want to know all about pharmacists' compensation and how happy they are with their jobs.

Tailoring hepatitis C treatments to shorten regimen length can reduce costs and ease burden for patients with limited insurance benefits.

Cellular proliferation predominantly drives HIV persistence on antiretroviral therapy, according to a new study.

With this approval, venetoclax (Venclexta) offers a new treatment option for individuals who are unable to tolerate standard intensive chemotherapy.

With this approval, venetoclax (Venclexta) offers a new treatment option for individuals who are unable to tolerate standard intensive chemotherapy.

Glasdegib (Daurismo) is the first and only Hedgehog pathway inhibitor approved for the treatment of acute myeloid leukemia.

Glasdegib (Daurismo) is the first and only Hedgehog pathway inhibitor approved for the treatment of acute myeloid leukemia.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

FDA officials are warning that stopping treatment with the multiple sclerosis (MS) drug fingolimod (Gilenya) can cause severe worsening.

Tivozanib (Fotivda) improved progression-free survival and reduced risk of death in patients with highly refractory advanced or metastatic disease.